57.05
0.95%
-0.55
アフターアワーズ:
57.02
-0.03
-0.05%
Incyte Corp. (INCY) 最新ニュース
Company News For May 14, 2024
Zacks Investment Research
Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday?
Benzinga
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks Investment Research
Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Zacks Investment Research
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Zacks Investment Research
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Zacks Investment Research
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Benzinga
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Benzinga
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Zacks Investment Research
Novartis (NVS) to Undertake Job Cuts in Development Department
Zacks Investment Research
Agilent (A) is Set for Analytica 2024 With Advanced Products
Zacks Investment Research
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Zacks Investment Research
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
Zacks Investment Research
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
Zacks Investment Research
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Benzinga
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
Benzinga
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Zacks Investment Research
Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings
Zacks Investment Research
Incyte (INCY) Lags Q4 Earnings and Revenue Estimates
Zacks Investment Research
Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY
Zacks Investment Research
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
Zacks Investment Research
Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Zacks Investment Research
Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug
Zacks Investment Research
Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition
Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
Zacks Investment Research
Here are Wall Street’s favorite stocks in the sector expected to grow profits the most in 2024
MarketWatch
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Benzinga
Here are Wall Street’s favorite stocks in the sector expected to grow profits the most in 2024
MarketWatch
Expert Ratings for Incyte
Benzinga
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
Zacks Investment Research
Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
Zacks Investment Research
MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study
Zacks Investment Research
Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness
Benzinga
The Latest Analyst Ratings for Incyte
Benzinga
大文字化:
|
ボリューム (24 時間):